Published on 19 April 2012
EASL: Telaprevir avoids side-effects in hepatitis
New data for the hepatitis C virus (HCV) treatment telaprevir (INCIVO) suggest that it may offer reliable efficacy with improved tolerability.
The results, to be released at the 47th annual meeting of the European Association for Study of the Liver (EASL) on Saturday, 21st April 2012, show that sustained virologic response (SVR) rate is unaffected by ribavirin dose reduction during treatment with telaprevir plus peginterferon alfa and ribavirin in treatment naïve and previously treated patients with genotype-1 chronic HCV.
The data also suggest that timing, duration and extent of ribavirin dose reduction may not substantially impact SVR.
Ribavirin dose reduction is often used to manage treatment-related anaemia, a common side-effect of HCV treatment
Additional telaprevir data to be presented at EASL included a cost-effectiveness analysis which demonstrates that the addition of telaprevir to peginterferon alfa and ribavirin (PR) is cost-effective for both treatment-naïve and experienced patients with genotype-1 chronic HCV, regardless of IL28B subtype.